TR200002995T2 - Folik asit ihtiva eden farmasötik bileşimler, bununla ilgili yöntemler ve uygulama sistemleri - Google Patents

Folik asit ihtiva eden farmasötik bileşimler, bununla ilgili yöntemler ve uygulama sistemleri

Info

Publication number
TR200002995T2
TR200002995T2 TR2000/02995T TR200002995T TR200002995T2 TR 200002995 T2 TR200002995 T2 TR 200002995T2 TR 2000/02995 T TR2000/02995 T TR 2000/02995T TR 200002995 T TR200002995 T TR 200002995T TR 200002995 T2 TR200002995 T2 TR 200002995T2
Authority
TR
Turkey
Prior art keywords
pharmaceutical compositions
folic acid
compositions containing
related methods
application systems
Prior art date
Application number
TR2000/02995T
Other languages
English (en)
Inventor
E. Kafrissen Michael
Jr. Godfrey P.Oakley
Original Assignee
Ortho-Mcneil Pharmaceutical,Inc.
Sa�. Ve Sos.Yrd.Bakanli�I Tar. Tems�L Ed�Len A.B.D H�K�Met�
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho-Mcneil Pharmaceutical,Inc., Sa�. Ve Sos.Yrd.Bakanli�I Tar. Tems�L Ed�Len A.B.D H�K�Met� filed Critical Ortho-Mcneil Pharmaceutical,Inc.
Publication of TR200002995T2 publication Critical patent/TR200002995T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Söz konusu bulus ya oral bir dogum kontrol maddesi ya da hormon replasmani bilesiminden olusan ve folik asit ihtiva eden farmasötik bilesimler ile ilgilidir.Bulus ayrica farmasötik bilesimler vasitasiyla folik asitin bir özneye hazir bir sekilde verilmesi ile yöntemleri de kapsar.Buna ilave olarak hazir farmasötik bilesimlerin uygulanmasi için faydali olan bir ilaç sunum sistemi de bulusun kapsami içindedir.
TR2000/02995T 1998-04-17 1999-04-16 Folik asit ihtiva eden farmasötik bileşimler, bununla ilgili yöntemler ve uygulama sistemleri TR200002995T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8206898P 1998-04-17 1998-04-17

Publications (1)

Publication Number Publication Date
TR200002995T2 true TR200002995T2 (tr) 2001-01-22

Family

ID=22168860

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/02995T TR200002995T2 (tr) 1998-04-17 1999-04-16 Folik asit ihtiva eden farmasötik bileşimler, bununla ilgili yöntemler ve uygulama sistemleri

Country Status (8)

Country Link
US (1) US6190693B1 (tr)
EP (2) EP1071428A2 (tr)
JP (3) JP2002512185A (tr)
CN (2) CN1644201A (tr)
AU (4) AU3567699A (tr)
CA (2) CA2522761C (tr)
TR (1) TR200002995T2 (tr)
WO (1) WO1999053910A2 (tr)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060281723A1 (en) * 1999-04-16 2006-12-14 Kafrissen Michael E Folic acid-containing pharmaceutical compositions, and related methods and delivery systems
US7297688B2 (en) 2000-06-08 2007-11-20 Wyeth Starter kit for low dose oral contraceptives
US20040002482A1 (en) * 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
WO2002047693A2 (en) * 2000-12-14 2002-06-20 Ortho-Mcneil Pharmaceutical, Inc. Steroid hormone products comprising a stabilizing agent in non-crystalline form
PL367094A1 (en) 2001-07-31 2005-02-21 Pfizer Products Inc. Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins
US6911438B2 (en) * 2001-09-12 2005-06-28 Jonathan V. Wright Hormone replacement formulation
ES2274107T3 (es) * 2002-02-21 2007-05-16 Bayer Schering Pharma Ag Composiciones farmaceuticas comprendiendo uno o mas esterioides, uno o mas componentes de tetrahidrofolato vitamina b12.
EP1490076A4 (en) * 2002-03-11 2010-01-06 Lipomics Technologies Inc NEW METABOLIC TARGETS AND MARKERS
AU2003239869A1 (en) * 2002-05-23 2003-12-12 Michael Holick Use of a parathyroid hormone peptide analogs for the treatment of vaginal atrophy
US20040162292A1 (en) * 2002-12-03 2004-08-19 Evenstad Kenneth L. Multivitamin formulations for promoting healthy collagen, and methods of their use
DE102004026671A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Darreichungsform zur hormonalen Kontrazeption
DE102004026669A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Verwendung einer Kombination aus Ethinylestradiol und Chlormadinonacetat zur Herstellung eines Arzneimittels
SI1755562T1 (sl) 2004-05-28 2014-02-28 Richter Gedeon Nyrt. Kontracepcijsko sredstvo, ki vsebuje folno kislino
DE102004026679A1 (de) 2004-05-28 2005-12-15 Grünenthal GmbH Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat
DE102004026670A1 (de) 2004-05-28 2005-12-15 Grünenthal GmbH Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat
US20070088012A1 (en) * 2005-04-08 2007-04-19 Woun Seo Method of treating or preventing type-2 diabetes
AU2012227235B2 (en) * 2005-05-13 2015-06-11 Bayer Intellectual Property Gmbh Pharmaceutical composition comprising progestogens and/or estrogens and 5-methyl-(6S)-tetrahydrofolate
UY29527A1 (es) * 2005-05-13 2006-12-29 Schering Ag Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.
DE102005034498A1 (de) * 2005-07-20 2007-01-25 Grünenthal GmbH Orale Kontrazeption mit Trimegeston
US7901710B2 (en) * 2005-08-04 2011-03-08 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
US7998500B2 (en) * 2005-08-04 2011-08-16 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
US8263137B2 (en) * 2005-08-04 2012-09-11 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
US8202546B2 (en) 2005-08-04 2012-06-19 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
CN101287470B (zh) 2005-10-12 2012-10-17 优尼麦德药物股份有限公司 改良的睾酮凝胶及使用方法
DE102005053771A1 (de) * 2005-11-09 2007-05-10 Grünenthal GmbH Darreichform zur hormonalen Kontrazeption
CN101489563A (zh) * 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 用于避孕和预防先天性畸形风险的药物制剂
DE112007001600A5 (de) * 2006-07-06 2009-04-30 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Zusammensetzung zur Kontrazeption und zur Verminderung des Risikos angeborener Fehlbildungen
US8617597B2 (en) 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid
US20080039485A1 (en) * 2006-08-08 2008-02-14 Targetgen Biotechnology Co., Ltd. Low-dose-long-term pharmaceutical composition comprising camptothecin derivatives for the treatment of cancers
CA2713377A1 (en) * 2008-02-06 2009-08-13 Universiteit Antwerpen Protective effect of high dose folate on mycardial ischemia
US20110097405A1 (en) * 2008-02-13 2011-04-28 Bayer Schering Pharma Aktiengesellschaft Estradiol-containing drug delivery system
UY32836A (es) 2009-08-12 2011-03-31 Bayer Schering Pharma Ag Partículas estabilizadas que comprenden 5-metil-(6s)-tetrahidrofolato
BR112012021372B8 (pt) 2010-02-26 2021-05-25 Centro Nac De Tecnologia Y Seguridad Alimentaria Laboratorio Del Ebro processo para produção de nanopartículas, nanopartícula produzida pelo referido processo, composição e gênero alimentício
US10357496B2 (en) * 2011-11-05 2019-07-23 South Alabama Medical Science Foundation Methods, formulations, and kits for rapidly repleting folate levels in women
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CA2940454A1 (en) * 2014-03-10 2015-09-17 Benjamin M. YU Methods and compositions for transdermal delivery
JP2017516768A (ja) 2014-05-22 2017-06-22 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 天然の併用ホルモン補充療法剤及び療法
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
ES2941360T3 (es) * 2015-09-20 2023-05-22 Univ Ariel Res & Dev Co Ltd Composiciones antihemorrágicas
EP3435977A4 (en) 2016-04-01 2019-10-16 Therapeuticsmd, Inc. PHARMACEUTICAL COMPOSITION OF STEROID HORMONE
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
WO2020227580A1 (en) * 2019-05-07 2020-11-12 Optimed Technology, Inc. Materials and methods for drug-induced gingival overgrowth
WO2023168365A1 (en) * 2022-03-02 2023-09-07 Jds Therapeutics, Llc Polyglutamic acid compositions and methods of using

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2131292B (en) * 1982-12-01 1987-03-11 Dr Christopher H Mortimer Progestational pharmaceutical formulations
AU582540B2 (en) * 1983-08-05 1989-04-06 Pre Jay Holdings Ltd. A method of hormonal treatment of perimenopausal, menopausal and post-menopausal disorders and multi-preparation pack therefor
WO1988004927A1 (en) * 1986-12-31 1988-07-14 Davirand, Inc. Compositions and formulations containing folic acid, method of treating tissue with folic acid and method for preparing compositions and formulations of folic acid
DE4429398C2 (de) * 1994-08-09 1997-09-11 Jenapharm Gmbh Verwendung von Estra-1,3,5(10)-trien-Derivaten zur hormonalen Kontrazeption
CA2261764A1 (en) * 1996-07-30 1998-02-05 Jeffrey B. Blumberg Dietary supplements
HUP9900213A1 (hu) * 1999-02-01 2000-12-28 Gábor Bogye Gyógykompozíció(k) gesztagén tipusú hormon tartalmú gyógyszerek thromb-embóliás mellékhatásainak mérséklésére

Also Published As

Publication number Publication date
AU2006213981A1 (en) 2006-10-19
CN1300218A (zh) 2001-06-20
CA2329005A1 (en) 1999-10-28
WO1999053910A3 (en) 1999-12-29
AU3567699A (en) 1999-11-08
WO1999053910A8 (en) 2001-07-05
AU2003262426B2 (en) 2006-09-28
CA2522761C (en) 2010-07-06
WO1999053910A2 (en) 1999-10-28
AU2009238379B2 (en) 2013-01-10
AU2003262426A1 (en) 2003-12-11
EP2002839A1 (en) 2008-12-17
CA2522761A1 (en) 1999-10-28
JP2009298797A (ja) 2009-12-24
JP2009298796A (ja) 2009-12-24
AU2009238379A1 (en) 2009-12-17
CN1240387C (zh) 2006-02-08
JP2002512185A (ja) 2002-04-23
AU2003262426A8 (en) 2003-12-11
CN1644201A (zh) 2005-07-27
CA2329005C (en) 2006-01-03
US6190693B1 (en) 2001-02-20
EP1071428A2 (en) 2001-01-31

Similar Documents

Publication Publication Date Title
TR200002995T2 (tr) Folik asit ihtiva eden farmasötik bileşimler, bununla ilgili yöntemler ve uygulama sistemleri
Clausen et al. The role of glutathione in the permeation enhancing effect of thiolated polymers
BR9901068A (pt) Dispersão aquosa, sua aplicação e pó redispersável.
TR199800743A2 (tr) Ispençiyari uygulamaya mahsus devamli salivermeli polimer karisim matrisi.
TR200002771T2 (tr) Devamlı salımı olan preparatlar
BR9611802A (pt) Composições farmacêuticas
DE69524772D1 (de) Ophthalmologisches abgabesystem
DE69820671D1 (de) Zubereitung zur nasalen verabreichung enthaltend vibrio cholera zonula occludens toxin als absorptionsvermittler
CA2478621A1 (en) Botulinum toxin pharmaceutical compositions
TR199903214T2 (tr) Bir antitümör maddesi ve bir hidroksimik asit türevini ihtiva eden, antitümör etkinligi arttirilmis ve yan etkileri düsürülmüs farmasötik bilesim.
NO20000284L (no) Garvesyre-polymerblandinger for kontrollert frigivelse av farmasøytiske midler, særlig i munnhulen
DE69929703D1 (de) Neue orale formulierungen für 5-ht4 agonisten oder antagonisten
TR200400234T4 (tr) ''Stabil, nazal, oral veya sublingual uygulanabilen, desmopressin ihtiva eden farmasötik preparasyon''
ES2168457T3 (es) Composiciones farmaceuticas que comprenden una superoxido dismutasa.
AU6821687A (en) System for delivering drug with enhanced bioacceptability
EA200200914A1 (ru) Система контроля дозирования для однократного ежедневного приема назначенного ципрофлоксацина
ATE199641T1 (de) Terpenderivate (sarcodictyine) als antikrebsmittel
ATE256134T1 (de) Sulfatierte phosphatidylinositole, ihre herstellung und verwendung
PT1231908E (pt) Composicao farmaceutica compreendendo um composto dador de no e sua utilizacao em terapia
BR9908394A (pt) Composições de hidroxipropilcelulose e de polìmero aniÈnico e uso das mesmas como revestimentos de pelìcula farmacêuticos
AU5024599A (en) Pharmaceutical composition with antitumor activity on the basis of carboplatin
MY128958A (en) New oral formulation for 5-ht4 agonists or antagonists.
MY102368A (en) Solid sustained-release composition
TR199801520A1 (tr) Kristalimsi progestajenler.
BR0016737A (pt) 14,15-ciclopropano-androstanos insaturados, processos para a sua preparação e composições farmacêuticas contendo estes compostos